2-21001867-T-A
Variant names: 
Variant summary
Our verdict is Uncertain significance. The variant received 4 ACMG points: 4P and 0B. PVS1_ModeratePM2
The NM_000384.3(APOB):c.13555A>T(p.Arg4519*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
 Genomes: not found (cov: 32) 
Consequence
 APOB
NM_000384.3 stop_gained
NM_000384.3 stop_gained
Scores
 2
 2
 3
Clinical Significance
 Not reported in ClinVar 
Conservation
 PhyloP100:  1.37  
Publications
0 publications found 
Genes affected
 APOB  (HGNC:603):  (apolipoprotein B) This gene product is the main apolipoprotein of chylomicrons and low density lipoproteins (LDL), and is the ligand for the LDL receptor. It occurs in plasma as two main isoforms, apoB-48 and apoB-100: the former is synthesized exclusively in the gut and the latter in the liver. The intestinal and the hepatic forms of apoB are encoded by a single gene from a single, very long mRNA. The two isoforms share a common N-terminal sequence. The shorter apoB-48 protein is produced after RNA editing of the apoB-100 transcript at residue 2180 (CAA->UAA), resulting in the creation of a stop codon, and early translation termination. Mutations in this gene or its regulatory region cause hypobetalipoproteinemia, normotriglyceridemic hypobetalipoproteinemia, and hypercholesterolemia due to ligand-defective apoB, diseases affecting plasma cholesterol and apoB levels. [provided by RefSeq, Dec 2019] 
APOB Gene-Disease associations (from GenCC):
- hypercholesterolemia, autosomal dominant, type BInheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, G2P, Labcorp Genetics (formerly Invitae), ClinGen, Ambry Genetics
 - familial hypobetalipoproteinemia 1Inheritance: AR, AD, SD Classification: DEFINITIVE, STRONG Submitted by: PanelApp Australia, Labcorp Genetics (formerly Invitae), Genomics England PanelApp, ClinGen
 - homozygous familial hypercholesterolemiaInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
 
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Uncertain_significance. The variant received 4 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most exon, not predicted to undergo nonsense mediated mRNA decay. Fraction of  0.01 CDS is truncated, and there are 0 pathogenic variants in the truncated region.
PM2
Very rare variant in population databases, with high coverage; 
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes  Cov.: 32 
GnomAD3 genomes 
Cov.: 
32
GnomAD4 exome Cov.: 31 
GnomAD4 exome 
Cov.: 
31
GnomAD4 genome  Cov.: 32 
GnomAD4 genome 
Cov.: 
32
ClinVar
Not reported inComputational scores
Source: 
Name
Calibrated prediction
Score
Prediction
 BayesDel_addAF 
 Pathogenic 
D 
 BayesDel_noAF 
 Pathogenic 
 DANN 
 Uncertain 
 Eigen 
 Uncertain 
 Eigen_PC 
 Benign 
 FATHMM_MKL 
 Benign 
D 
 PhyloP100 
 Vest4 
 GERP RS 
Splicing
Name
Calibrated prediction
Score
Prediction
 SpliceAI score (max) 
Details are displayed if max score is > 0.2
 Find out detailed SpliceAI scores and Pangolin per-transcript scores at 
Publications
 You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.